Preoperative Statin Therapy is not Associated with Biochemical Recurrence After Radical Prostatectomy: Our Experience and Meta-Analysis

Mass, Alon; Agalliu, Ilir; Laze, Juliana; Lepor, Herbert

doi:10.1016/j.juro.2012.05.011

Cited by 27 publications

(27 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…17 Furthermore, our study and three other studies on the effect of statins on the outcome of PC after RP did not show a lower PSA in patients taking statins at the time of surgery. 11,13,14 In contrast to the results of our and other previous studies, Hamilton et al 17 found statin use to be associated with decreased risk of BCR after RP after adjustment for clinical and pathological features. Adding Gleason-Score to their multivariable model generated the largest shift in HR for statin use.…”

Section: Discussioncontrasting

confidence: 99%

“…This observation is in line with five previously published studies [11][12][13][14][15] and a recent meta-analysis, 19 which could not reveal a significant association of statin use with BCR after RP. In contrast, Ritch et al detected an increased risk of BCR in PC patients using statins after RP.…”

Section: Discussionsupporting

confidence: 91%

“…Similar findings of subgroup analysis stratified by Gleason sum or D'Amico category were reported from previous studies. 12,14 BCR was found to be lower in PC patients with PSM taking statins compared with those not taking statins. Furthermore, in the subgroup of patients with PSM, statin use was independently associated with a decreased risk of BCR.…”

Section: Discussionmentioning

confidence: 84%

“…10 A total of seven studies investigated the association of statin use with BCR in PC patients treated with RP. Of these, five studies showed no association, [11][12][13][14][15] whereas in one study statin use was associated with increased 16 and in one study with decreased 17 risk of BCR.…”

Section: Introductionmentioning

confidence: 90%

See 3 more Smart Citations

Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy

Rieken

Kluth

Xylinas

et al. 2013

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 84%

Section: Introductionmentioning

confidence: 90%

See 2 more Smart Citations

Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy

Rieken

Kluth

Xylinas

et al. 2013

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…Regarding prostate cancer outcomes after treatment, three meta-analyses have reported a null association between statin use and risk of recurrence (Mass, et al 2012; Park, et al 2013; Scosyrev, et al 2013). However, the studies contributing to these meta-analyses were few and most examined statin use at the time of prostate cancer treatment.…”

Section: Obesity and Related Co-morbidities As Modifiable Lifestylmentioning

confidence: 99%

Obesity and cancer: mechanistic insights from transdisciplinary studies

Allott¹,

Hursting²

2015

Endocrine-Related Cancer

140

101

View full text Add to dashboard Cite

Obesity is associated with a range of health outcomes that are of clinical and public health significance, including cancer. Herein, we summarize epidemiologic and preclinical evidence for an association between obesity and increased risk of breast and prostate cancer incidence and mortality. Moreover, we describe data from observational studies of weight change in humans and from calorie restriction studies in mouse models which support a potential role for weight loss in counteracting tumor-promoting properties of obesity in breast and prostate cancers. Given that weight loss is challenging to achieve and maintain, we also consider evidence linking treatments for obesity-associated co-morbidities, including metformin, statins and non-steroidal anti-inflammatory drugs, with reduced breast and prostate cancer incidence and mortality. Finally, we highlight several challenges that should be considered when conducting epidemiologic and preclinical research in the area of obesity and cancer, including the measurement of obesity in population-based studies, the timing of obesity and weight change in relation to tumor latency and cancer diagnosis, and the heterogeneous nature of obesity and its associated co-morbidities. Given that obesity is a complex trait, comprised of behavioral, epidemiologic and molecular/metabolic factors, we argue that a transdisciplinary approach is the key to understanding the mechanisms linking obesity and cancer. As such, this review highlights the critical need to integrate evidence from both epidemiologic and preclinical studies to gain insight into both biologic and non-biologic mechanisms contributing to the obesity-cancer link.

show abstract

Exposure to statins post localized prostate cancer diagnosis and risk of metastasis among men who did not receive curative prostate cancer treatment

et al. 2022

View full text Add to dashboard Cite

Background: Few studies have evaluated the effect of statin exposure on metastasis risk among prostate cancer patients not receiving curative treatment. Methods:We included men diagnosed with localized prostate cancer at an integrated health care system between 1997 and 2006 who did not receive curative treatment within 6 months of diagnosis. We followed these men until a metastatic event, disenrollment, death, or 12/31/2016. We collected all data from electronic health records supplemented by chart review. We used Cox regressions to examine the association between post-diagnostic statin exposure and metastasis, controlling for clinical characteristics and pre-diagnostic statin exposure.Results: There were 4245 men included. Mean age of diagnosis was 68.02 years.46.6% of men used statins after prostate cancer diagnosis. During follow-up, 192 men developed metastasis (cumulative incidence rate: 14.5%). In the adjusted Cox model, statin use post-prostate cancer diagnosis was not significantly associated with a metastatic event (HR = 0.97, 95% CI = 0.69, 1.36). Pre-diagnostic statin use was also not associated with development of metastasis (HR = 0.76, 95% CI = 0.53, 1.10).We did not observe a dose-response for the proportion of person-time at-risk postprostate cancer diagnosis on statins (HR = 0.98 per 10% increase in person-time exposed [95% CI = 0.93, 1.03]). Conclusions:We did not find an inverse association between post-diagnosis statin exposure and metastasis development in localized prostate cancer patients who did not receive active treatment. Our results did not offer support to the chemopreventive potential of post-diagnostic statin use among men on active surveillance.

show abstract

Preoperative Statin Therapy is not Associated with Biochemical Recurrence After Radical Prostatectomy: Our Experience and Meta-Analysis

Abstract: Our findings are consistent with the results of the meta-analysis, which indicated that preoperative statin use does not impact the overall risk of biochemical recurrence.

Cited by 27 publications

References 24 publications

Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy

Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy

Obesity and cancer: mechanistic insights from transdisciplinary studies

Exposure to statins post localized prostate cancer diagnosis and risk of metastasis among men who did not receive curative prostate cancer treatment

Contact Info

Product

Resources

About